Diverting and injecting medication designed for oral use is extremely risky for young people. A new “film” formulation of buprenorphine-naloxone has been found to have similar diversion and injection rates as other formulations and methadone.

Various formulations of buprenorphine are available for young people as Opiate Replacement Therapies. New formulations  are often developed in order to discourage diversion and injection. In a recent study the new Buprenorphine-naloxone "film" formulation was diverted and injected at similar rates to both Buprenorphine-naloxone tablets and methadone but that buprenorphine on its own was diverted at higher rates.

Here is the paper.